{"id":18490,"date":"2019-04-01T00:00:00","date_gmt":"2019-04-01T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2019\/04\/01\/aacr-longer-survival-with-gilteritinib-in-flt3mut-aml\/"},"modified":"2019-04-02T16:10:10","modified_gmt":"2019-04-02T16:10:10","slug":"aacr-longer-survival-with-gilteritinib-in-flt3mut-aml","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2019\/04\/01\/aacr-longer-survival-with-gilteritinib-in-flt3mut-aml\/","title":{"rendered":"AACR: Longer Survival With Gilteritinib in <i>FLT3<\/i><sub>mut&#43;<\/sub> AML"},"content":{"rendered":"<h3>Longer overall survival, better remission rates seen for patients receiving gilteritinib versus salvage chemo<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>MONDAY, April 1, 2019 (HealthDay News) &#8212; For patients with FMS-like tyrosine kinase 3 (<i>FLT3<\/i>) mutations who have relapsed or refractory acute myeloid leukemia (AML), gilteritinib results in longer overall survival and higher response rates than salvage chemotherapy (SC), according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 29 to April 3 in Atlanta.<\/p>\n<p>Alexander E. Perl, M.D., from the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, and colleagues randomly assigned adults with confirmed <i>FLT3<\/i><sub>mut+<\/sub> AML refractory to induction chemotherapy or in untreated first relapse to receive either continuous 28-day cycles of 120 mg\/day gilteritinib (247 patients) or SC (124 patients).<\/p>\n<p>The researchers found that patients assigned to gilteritinib had significantly longer overall survival (9.3 versus 5.6 months; hazard ratio for death, 0.637; P = 0.0007); survival rates at one year were 37.1 and 16.7 percent, respectively. The rates of complete remission\/complete remission with partial hematologic recovery (CR\/CRh) were 34.0 and 15.3 percent for gilteritinib and SC, respectively (P = 0.0001); CR rates were 21.1 and 10.5 percent (P = 0.0106). For the gilteritinib and SC arms, median event-free survival was 2.8 and 0.7 months, respectively (hazard ratio, 0.793; P = 0.0830). Per patient-year, serious treatment-emergent adverse events were less common with gilteritinib than SC.<\/p>\n<p>&#8220;Across the board, this trial shows gilteritinib carries a clear survival benefit, meaning we now have a targeted, highly-effective, and well-tolerated treatment option for a group of truly high-risk patients,&#8221; Perl said in a statement.<\/p>\n<p>Gilteritinib is manufactured by Astellas Pharma, which funded the study.<\/p>\n<p><a href=\"https:\/\/www.aacr.org\/Newsroom\/Pages\/News-Release-Detail.aspx?ItemID=1295\" target=\"_new\">Press Release<\/a><\/p>\n<p><a href=\"https:\/\/www.aacr.org\/Meetings\/Pages\/MeetingDetail.aspx?EventItemID=174\" target=\"_new\">More Information<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2019 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Longer overall survival, better remission rates seen for patients receiving gilteritinib versus salvage chemo<\/p>\n","protected":false},"author":6,"featured_media":18510,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-18490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/18490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=18490"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/18490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/18510"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=18490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=18490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=18490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}